Moderna Covid vaccine wins full FDA approval, Novavax files EUA; a shift in the DNA-sequencing market

The ever-evolving landscape of Covid-19 vaccines changed again on Monday. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Moderna wins full approval for its Covid-19 vaccine, as Novavax seeks authorization for its version By Helen Branswell Sergio Flores/Getty Images The development came as Novavax submitted a long-awaited application to the FDA for an emergency use authorization for its vaccine. Read More STAT+: Illumina's embrace of long-read technology signals a shift in the DNA-sequencing market By Jonathan Wosen Adobe Long-read technology is an approach that could help diagnose rare diseases and decipher parts of the human genome that remain a mystery. Read More Opinion: A devil's choice: Take an immune-suppressing drug and risk getting Covid or watch my wrist joints disintegrate? By Larry Tye Sean Gallup/Getty Images Should I take immune-suppressing Humira for my rheumatoid arthritis and risk Covid-19, or not take it and live with pain and joint damage? Read More Sponsor content by STAT Events The Exhaustion Epidemic: Examining the Covid-19 Burnout Crisis in Health Care Join STAT on Feb. 7 to discuss the solutions needed to support and retain health care workers experiencing burnout at unprecedented levels. Register here. STAT+: Will the Biden administration approach march-in rights like Trump? Fight over pricey cancer drug offers a test By Ed Silverman Adobe “The fact that NIH is even contemplating march-in is significant," said Robert Cook-Deegan, a professor at Arizona State University. Read More STAT+: Madrigal drug for fatty liver disease clears safety hurdle in first of two late-stage studies By Adam Feuerstein Adobe Madrigal is seeking to be the first company to win approval for a drug to treat NASH — a potentially lucrative commercial opportunity. Read More STAT+: In the heart of the booming biotech industry, workers are in short supply By Anissa Gardizy — Boston Globe David L. Ryan/Boston Globe With every snew company that comes out of stealth mode or a mega-funding round, the people problem has gotten worse. Read More Opinion: The hospital of the future won't be what you expect By Rob Rohatsch Daniel Cole/AP Radical changes afoot will lead to hospital-quality care being administered in primary and urgent care centers and in people's homes. Read More Monday, January 31, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser